Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1103a and T-DXd in Advanced Solid Tumors
NCT05765851Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2023
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of DS-1103a in solid tumor (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting Toxicities, Objective Response Rate and 1 more. Started May 2023; status: recruiting.
02
Drugs
DS-1103a
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05765851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765851.